Read the 2016 liquid biopsy market policy

With a tube of blood to detect cancer, this is the common dream of the global medical community for decades. Liquid biopsy techniques attempt to capture relevant tumor information from the blood using a variety of techniques, thereby circumventing the limitations of traditional methods requiring surgery and puncture sampling. This article will present progress in the field of in vitro biopsy in 2016 from multiple dimensions such as technology, research, market, capital, and policy.

"Liquid biopsy" new technology

At present, the tests involved in body fluid biopsy mainly include the detection of free circulating tumor cells (CTCs), tumor DNA (ctDNA), circulating RNA (Circulating RNA) and exosomes (having a variety of proteins related to cell origin, Lipids, DNA, RNA, etc.). Among them, ctDNA, RNA and exosomes are substances secreted by the tumor itself or released when the tumor cells die.

CTC detection is easy to enrich, ctDNA enrichment is difficult to detect, ctDNA has a strong tumor representative, and exosomes have strong stability. (For details, see Flint's liquid biopsy report in the middle of 2016. "Liquid biopsy" global investment and financing list hits!|hsmap series)

一文读懂2016液体活检市场相关政策

Table 1. Comparison of liquid biopsy techniques

2016 research new findings / new developments

In recent years, the research heat of liquid biopsy has been rising, and the results have become more and more significant, especially in the field of tumor resistance. What changes will the liquid biopsy bring to cancer treatment? Let's take a look at some of the results of the 2016 study. (News from the HSMAP information section)

一文读懂2016液体活检市场相关政策

Table 2. Clinical study quantity time distribution

一文读懂2016液体活检市场相关政策

table 3. Annual patent application (orange line), public quantity trend

According to the data analysis report created by Flint, the number of patents for liquid biopsy has increased rapidly. The number of clinical studies is also on the rise. At present, 16 domestic clinical trials have reached 66 cases, indicating that liquid biopsy technology is receiving more and more attention in basic scientific research.

一文读懂2016液体活检市场相关政策

Table 4. Liquid biopsy indication distribution pie chart

ANSI Class 3

ANSI Class 3 Safety Shirt,Hi Vis ANSI Class 3 Vest,ANSI Class 3 Jacket

Ningbo Staneex Imp. & Exp. Co., Ltd. , https://www.staneex.com

Posted on